Clinical evidence dossier
Insulin therapy
Time in range
Evidence signal
Evidence signal
Strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 5
- Supporting studies available for review
- 5
- Randomized trials
- 4
- Reported effects
- 24
Clinical conclusion
Insulin therapy shows a moderate positive evidence signal for improving Time in range across the studied comparisons.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
61.2% to 61.2%
Between-group effect
Absolute change
−15.6% to −15.6%
Between-group effect
Absolute change
12 percentage points to 12 percentage points
Change from baseline
Mean difference
−21.01% to 18.58%
Between-group effect
Mean difference
15.2% to 15.2%
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 1
- Magnitude-eligible effects
- 6
Consistency
Consistency classification
Mostly consistent
- Positive
- 3
- No effect
- 0
- Mixed
- 0
- Negative
- 2
Population and applicability
Structured population data were available for 5 of 5 supporting studies. Diabetes type was heterogeneous: 2 studies with type 1 diabetes, 2 studies with type 2 diabetes. 3 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Young Adult (19–39)
- Middle Aged (40-64)
- Older Adults (65+)
- Male
- Female
- with T1 Diabetes
- Individuals with type 1 diabetes.
- Participants using insulin delivery systems.
- Participants currently using insulin therapy.
- Adults with Type 2 diabetes undergoing surgery.
- Patients requiring insulin therapy during the perioperative period.
- Adults diagnosed with type 2 diabetes
Limitations
- Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.
- 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.
- 4 of 5 studies with duration data have follow-up of 12 weeks or less.
- 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.